Amicus Therapeutics Inc (FOLD NASDAQ) stock market data APIs
$9.9621
0.01(0.1%)
as of December 5, 2025
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
9.9621
Open
9.9685
High
9.9685
Low
9.8577
52 wk Range
5.51-10.57
Market Cap
3 054 M
Shares Outstanding
309 M
Revenue
599 M
EPS
0.17
Beta
0.461
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Amicus Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
ILDR.US
First Trust Exchange-Traded Fund VIII - First Trust Innovation Leaders ETF
3.14
(10.38%)
0.88
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 599 M
- EBITDA: 42 120 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 0.0234
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock
Amicus Therapeutics (FOLD) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue s...
Can Galafold Continue to Drive Amicus' Top Line in 2026?
Amicus Therapeutics FOLD has been making meaningful progress with its lead product, Galafold (migalastat), which has been driving the majority of the company’s revenues. The drug has remained a key ...
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Amicus Therapeutics (FOLD). Shares have added about 6.4% in that time frame, outperforming the S&P 500. Will the recent positive trend con...
BMY Gains on News of Continuation of Alzheimer's Disease Study
Shares of Bristol Myers Squibb BMY gained 5.62% after the company announced the continuation of the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The news cheer...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
